Ipamorelin: a clean mechanism attached to a failed trial

The short version

Ipamorelin is a synthetic peptide five amino acids long. It switches on the ghrelin receptor in the pituitary gland, which releases a pulse of growth hormone. What made it notable in the 1990s is what it does not do: unlike the growth-hormone-releasing peptides that came before it, it does not meaningfully raise the stress hormone cortisol or the hormone prolactin, even at very high amounts in animals ^[11].

That clean profile is the whole reason it is still discussed. The clinical record behind it is much less flattering. Its only published Phase 2 trial in people, in patients recovering from bowel surgery, did not meet its main goal ^[8]. It has never been approved as a medicine anywhere, and there is no long-term human safety database.

Ipamorelin is the lead compound on this desk because it shows how far good mechanistic description can travel without clinical proof — and how easily that description gets repeated as though it were proof.

What ipamorelin is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two unnatural D-amino acids and an alpha-aminoisobutyric acid residue make it resistant to the enzymes that would otherwise chew it up quickly. It was derived from the earlier peptide GHRP-1 by removing a central Ala-Trp dipeptide, and it appears in the literature as NNC 26-0161 and as ipamorelin acetate.

Pharmacologically it is a selective agonist of the ghrelin receptor, formally the growth hormone secretagogue receptor GHS-R1a. It has never been approved as a drug for any indication by the FDA, the EMA or any other regulator, and the lack of approval reflects a failed efficacy programme rather than a development that simply stalled. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk drug substances list following the nominator's withdrawal, and reviewed the acetate and free base at an October 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is prohibited in sport at all times as a growth hormone secretagogue, and accredited anti-doping laboratories can detect it in urine.

How it works

Ipamorelin binds the ghrelin receptor on pituitary somatotrophs — the cells that store and release growth hormone — and triggers a discrete pulse of that hormone. The route is distinct from, and complementary to, the one used by growth-hormone-releasing hormone, which is the pharmacological rationale behind pairing it with GHRH analogues in the protocols discussed online.

Its founding characterisation established the selectivity that defines it. In primary rat pituitary cells, anaesthetised rats and conscious swine, ipamorelin released growth hormone potently — a swine half-maximal effective dose of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 — yet did not raise ACTH or cortisol above the level seen with growth-hormone-releasing hormone itself, even at doses more than 200-fold above the growth-hormone half-maximal dose ^[11]. That characterisation was acute, not chronic, which is a distinction worth holding on to.

Human pharmacokinetics were mapped once, in healthy male volunteers given five fifteen-minute intravenous infusions across a range of 4.21 to 140.45 nmol/kg, eight volunteers per dose level. Kinetics were dose-proportional, terminal half-life was about two hours, clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg, and the growth hormone response arrived as a single discrete pulse peaking around forty minutes after dosing ^[9]. The receptor is also expressed outside the pituitary — on vagal and enteric neurons involved in gastric motility, on pancreatic islet cells, and in the hypothalamic circuitry that governs appetite — which is where the compound's off-target character comes from.

What the research actually shows

The defining human result is a negative one. In the only published Phase 2 randomised controlled trial, 114 adults undergoing bowel resection received 0.03 mg/kg intravenously twice daily for up to seven days. Median time to a first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, which did not reach statistical significance (p=0.15); the primary endpoint was missed. Treatment-emergent adverse events occurred in 87.5 per cent of the ipamorelin arm and 94.8 per cent of the placebo arm, so no ipamorelin-specific safety signal emerged in that short perioperative window ^[8].

In animals the compound does measurable things. Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided three times daily for fifteen days, raised the longitudinal bone growth rate of adult female rats from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively — with no change in total IGF-1, IGF-binding proteins or bone turnover markers, which points to a partly local, pulse-driven skeletal effect rather than a systemic one ^[10].

The most recent published in-vivo work is a 2024 ferret study of chemotherapy-induced weight loss. Intraperitoneal ipamorelin at 1–3 mg/kg inhibited cisplatin-induced body-weight loss by roughly 24 per cent on the last day of the delayed phase, but had no anti-emetic effect on either acute or delayed vomiting — in contrast to intracerebroventricular anamorelin, which cut acute emesis by 60 per cent ^[6]. The finding is interesting precisely because it separates a peripheral weight effect from a central anti-nausea one.

A 2026 orthopaedic narrative review reports that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a mouse model of glucocorticoid-induced muscle loss, while stating that the evidence is limited to animal studies and that safety and dosing data for ipamorelin remain unknown, with significant further research required before clinical recommendations can be made ^[12]. The popular combination protocol rests on separate single-agent pharmacology, not on trials of the combination for any outcome in people.

Reported effects, cautions and safety

What follows is anecdotal, not clinical evidence: it is drawn from research-use community reports and clinic write-ups, describes material of unknown identity and unverified content, and carries no doses.

Deeper, more restorative sleep is the most consistently cited benefit and is frequently reported, often with vivid dreams in the first week or two that settle afterwards. Faster physical recovery and less post-training soreness are frequently reported. A gradual shift toward a leaner appearance over weeks to months is reported occasionally, and is heavily confounded by whatever else the person was doing at the time.

Adverse reports cluster around the injection and the receptor. Facial flushing and a head-rush shortly after injecting are frequently reported and often compared to a niacin flush. Tingling or numbness in the hands and feet, mild puffiness or water retention, increased hunger in the hours after a dose, early lightheadedness or a spacey feeling, and injection-site redness or itching are each reported occasionally. So is a fading of the perceived effect after several months of uninterrupted use, which is the usual justification offered in forums for cycling on and off.

The cited cautions are more serious than the anecdote suggests. Growth hormone drives hepatic IGF-1 production, and IGF-1 is a well-characterised mitogen, so raising growth-hormone pulse amplitude repeatedly carries a theoretical concern in anyone with an existing or occult malignancy; the concern is mechanistic and class-level, with no ipamorelin-specific carcinogenicity study in humans ^{[10] [11]}. Growth hormone is also a counter-regulatory hormone that reduces insulin sensitivity, and preclinical work indicates a separate direct effect on pancreatic islet cells, so the net glycaemic effect in anyone with existing insulin dysregulation is unpredictable and no human glycaemic data exist at research-use exposures ^[11]. A 28-day integrated safety study of a structurally distinct agonist at the same receptor found dose-dependent myocardial degeneration and necrosis in rats, visible on histopathology and electron microscopy and accompanied by raised heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated; ipamorelin itself was not the tested compound, and no equivalent long-duration cardiovascular study of ipamorelin exists in any species ^[7]. Ghrelin-receptor agonism is orexigenic and adipogenic at the class level, and preclinical work suggests part of the body-composition effect is independent of the growth hormone axis, which matters for anyone whose condition would be worsened by increased appetite or fat deposition.

The largest caution is the absence of evidence. The only controlled human dataset is that single short perioperative trial ^[8], plus an acute single-dose pharmacokinetic study ^[9]. No Phase 3 trial has been conducted and no long-term human safety database exists, while the dominant route in off-label research use — subcutaneous self-administration — has no published safety or pharmacokinetic characterisation in humans at all. Material moving through unregulated channels is not subject to pharmaceutical quality assurance, so peptide identity, purity and sterility are unverified. These are documented gaps, not hypotheticals. The one genuine relative advantage is the selectivity itself: unlike less selective growth-hormone-releasing peptides, ipamorelin does not meaningfully raise ACTH, cortisol or prolactin in the animal characterisation, which removes the adrenocortical and hyperprolactinaemia concerns that apply to that older class ^[11].

Where ipamorelin sits in the identity question

Ipamorelin makes the identity problem unusually concrete, because its signature effect is measurable and its signature claim is not.

The compound's defining property — a growth hormone pulse without a cortisol or prolactin rise — was established by assaying hormones in blood, in animals, using characterised material ^[11]. Nothing about a personal experience can test that property. A person who reports better sleep has not measured a growth hormone pulse, does not know whether the preparation contained ipamorelin, and has no way to distinguish the peptide from the ritual, the expectation, or the several other things typically taken alongside it.

The gap is wider still because the effects most often reported in communities — sleep quality, recovery, body composition — are precisely the outcomes that no ipamorelin trial has ever measured. The one trial that exists measured time to a tolerated meal after bowel surgery, and it missed ^[8]. So there is no clinical anchor to compare an anecdote against, and the preparation generating the anecdote has no assay behind it. Two unknowns multiplied together do not produce a weak signal. They produce no signal, and this desk declines to treat it as one.